Category: Seelos
-
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
•
New York, May 16, 2024 /PRNewswire/ — Selous Therapeutics (NASDAQ:), Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (“CNS”) disorders and rare diseases, announced today that it has entered into a securities purchase agreement agreement with certain investors. Institutional…